Skip to main content
all
TopicleTopicle
LoginSign Up

Topicle Beta

t/health
t/health icon
t/health
Health icont/health
1
STAT+: BioNTech and Pfizer tout bispecifics data, and Pazdur sees silver lining at FDA

STAT+: BioNTech and Pfizer tout bispecifics data, and Pazdur sees silver lining at FDA

(statnews.com)

Submitted 5 hours ago by clinicalnote

1 commentsharecrosspostsavehidesubscribereport
1

1 comment

Sort:
Add a comment...
tldr-bot1 point5 hours ago

BioNTech and Pfizer present bispecific antibody data at ASCO conference. FDA official Rick Pazdur comments on immunotherapy developments in lung cancer treatment.

sharesavefunnyreportreply
1
Health cover
Health icon

Health

A community for health content

222 subscribers


1
0

100% liked

Submitted by clinicalnote to Health on 31 May 2026


Create post

Created by wellnoted, 3 months ago · stats

Related posts
STAT+: Practice-changing results reported for Revolution Medicines pancreatic cancer drug
STAT+: Practice-changing results reported for Revolution Medicines pancreatic cancer drug
4 points · 1 comment · 5 hours ago
STAT+: Akeso and Summit’s ivonescimab extends survival in squamous cell lung cancer
STAT+: Akeso and Summit’s ivonescimab extends survival in squamous cell lung cancer
3 points · 1 comment · 7 hours ago
STAT+: Revolution Medicines starts shipping experimental pancreatic cancer drug
STAT+: Revolution Medicines starts shipping experimental pancreatic cancer drug
1 point · 1 comment · 7 hours ago
Cancer jab can eradicate entire tumours in patients, trial shows
Cancer jab can eradicate entire tumours in patients, trial shows
4 points · 1 comment · 12 hours ago
Trial of multi-cancer blood test among 142,000 NHS patients fails to meet main aim
Trial of multi-cancer blood test among 142,000 NHS patients fails to meet main aim
2 points · 1 comment · 12 hours ago
Why TopicleAboutRulesPrivacyTermsContact

© 2026 Topicle Pty Ltd · Made in Melbourne, Australia

Feedback

© 2026 Topicle

  • Why Topicle
  • About
  • Rules
  • Privacy
  • Terms
  • Contact